STOCK TITAN
  1. Home
  2. SEC-Filings
  3. TMDX

Transmedics Group SEC Filings

TMDX NASDAQ

Welcome to our dedicated page for Transmedics Group SEC filings (Ticker: TMDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Locating critical facts inside TransMedics’ filings can feel like performing surgery without imaging. FDA approvals, clinical-trial endpoints, and the economics of single-use perfusion sets are scattered across hundreds of pages, while executive stock moves appear moments before major organ-care milestones. That complexity makes TransMedics SEC filings explained simply an urgent need for analysts and clinicians alike.

Stock Titan solves the puzzle with AI that dissects every submission the instant it hits EDGAR. Whether you need a TransMedics annual report 10-K simplified summary or a flagged line-item from the latest TransMedics quarterly earnings report 10-Q filing, our platform translates technical language into plain English. Real-time alerts surface TransMedics Form 4 insider transactions real-time, while concise notes decode TransMedics 8-K material events explained. Key features:

  • AI-powered highlights of clinical data, R&D spend, and PMA supplements
  • Instant access to TransMedics insider trading Form 4 transactions and option grants
  • Side-by-side TransMedics earnings report filing analysis for trend spotting
  • Clear pointers to TransMedics proxy statement executive compensation details

Use these insights to monitor transplant-volume targets, assess reimbursement risks, or track TransMedics executive stock transactions Form 4 before material disclosures. From understanding TransMedics SEC documents with AI to exporting data for valuation models, Stock Titan keeps surgeons, investors, and industry observers a step ahead—no medical degree required.

Filing

[SCHEDULE 13G/A] TransMedics Group, Inc. SEC Filing

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other

FAQ

What is the current stock price of Transmedics Group (TMDX)?

The current stock price of Transmedics Group (TMDX) is $109.88 as of July 18, 2025.

What is the market cap of Transmedics Group (TMDX)?

The market cap of Transmedics Group (TMDX) is approximately 4.2B.

What is the core technology behind TransMedics Group?

TransMedics Group focuses on the Organ Care System (OCS), which is a portable device that maintains donor organs in near-physiologic conditions, thereby improving their viability before transplantation.

How does the Organ Care System differ from traditional organ preservation methods?

Unlike cold storage, the OCS replicates the body’s natural environment using warm perfusion, providing continuous real-time monitoring and optimization to assess organ viability more accurately.

What are the primary benefits of using TransMedics' technology in organ transplantation?

The technology helps expand the donor pool, improves post-transplant patient outcomes, reduces potential complications, and optimizes the logistical process for organ transportation.

How does TransMedics generate revenue?

TransMedics generates revenue through the commercialization of its OCS devices and complementary logistics services that ensure timely, safe transportation of donor organs.

What is TransMedics' approach to regulatory compliance?

The company emphasizes meeting stringent regulatory standards across various jurisdictions, securing necessary certifications, and conducting ongoing clinical evaluations to maintain quality and safety.

Who benefits from TransMedics’ Organ Care System?

The system benefits transplant recipients by enhancing the viability and quality of donor organs, and it aids transplant centers and healthcare providers in delivering improved clinical outcomes.

How does TransMedics contribute to advancing transplant technology?

Through continuous innovation and research in organ perfusion technology, along with a robust logistics network, TransMedics is redefining clinical practices in organ transplantation.

How does TransMedics position itself in a competitive market?

TransMedics differentiates itself with its specialized focus on ex-vivo perfusion, rigorous clinical validation, and the integration of technology with operational support, all of which foster improved patient care.
Stock TMDX logo
Transmedics Group

NASDAQ:TMDX

TMDX Rankings

#2660 Ranked by Market Cap
N/A Ranked by Dividends

TMDX Stock Data

4.22B
32.81M
3.5%
115.88%
27.72%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
ANDOVER